Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK279 a Highly Selective Oral TYK2 Inhibitor for the Treatment of Active Psoriatic Arthritis

Takeda TSE4502NYSETAK today announced positive topline results from its randomized doubleblind placebocontrolled multipledose Phase 2b trial evaluating TAK279 an investigational oral allosteric tyrosine kinase 2 TYK2 inhibitor with next generation selectivity in people with active psoriatic arthritis.

Related Keywords

Osaka ,Japan ,Gangolli ,Karnataka ,India ,Muromoto ,Akagawa ,New Orleans ,Louisiana ,United States ,Japanese ,American ,Mark Dole ,Jun Saito ,Greenwood Carriero ,Takeda Pharmaceuticals ,Exchange Commission ,American College Of Rheumatology ,Takeda Pharmaceutical Company Limited ,International Media ,American Academy Of Dermatology Annual Meeting ,Society For Investigative Dermatology Annual Meeting ,Topline Results ,Significantly Greater Proportion ,Psoriatic Arthritis Patients Achieved ,Positive Results ,Takeda Intends ,Full Clinical Results Will ,Upcoming Medical ,American College ,Andy Plump ,Fiscal Year ,Psoriasis Area ,Severity Index ,Tyrosine Kinase ,Annual Report ,Semin Arthritis ,Dermatology Annual ,Investigative Dermatology Annual ,Subjects With Active Psoriatic ,Immune Mediated Inflammatory ,Media Contact ,Takeda Tak279 Tyrosine Kinase 2 Tyk2 Phase 2b Study Psoriatic Arthritis Andy Plump Jak Inhibition Nct05153148 Jakstat Inflammatory Cytokine Diseases Psoriasis Rare Plasmaderived Therapies Oncology Neuroscience Vaccines ,